Company / Cash per Share
CRISPR Therapeutics AG Cash per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$3.62
FY2025
5-year range
$2.70 / $11.99
FY2021-FY2025
Trend
+4.2%
vs FY2024
Sector context
#55 of 204
Health Care
What the data says
At $3.62, CRISPR Therapeutics AG's cash per share ranks #55 of 204 in the Health Care sector. Cash per Share has fluctuated over the past 10 years, ranging from $0.17 in FY2016 to $18.20 in FY2019.
Based on SEC 10-K filings.
3.62 in FY2025 with a 5-year CAGR of -25.5%.
Declined from $4.87 to $3.62 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- +10.3%
- 5-Year CAGR
- -25.5%
- 10-Year CAGR
- -
Sector benchmark
#55 of 204 in Health CareTop 27% of 204This company $3.62 Sector average $73.19
▼
-95.0% below sector average
Key checks
Key Insights
- In FY2025, cash per share increased 4.2% year-over-year.
- Ranks #55 out of 204 companies in the Health Care sector.
- Peak cash per share was recorded in FY2019.
- Lowest cash per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.62 | +4.2% |
| FY2024 | $3.48 | -28.5% |
| FY2023 | $4.87 | +80.3% |
| FY2022 | $2.70 | -77.5% |
| FY2021 | $11.99 | -24.2% |
| FY2020 | $15.81 | -13.1% |
| FY2019 | $18.20 | +208.2% |
| FY2018 | $5.91 | -25.6% |
| FY2017 | $7.94 | +4546.9% |
| FY2016 | $0.17 | -99.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026